Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed ...

Genmab (GMAB) announced updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan, an investigational folate ...

Basophils trigger a cytokine cascade that improves antitumor immunity in mice, offering potential targets for cancer immunotherapy.

In these two cohorts presented at AACR, the combination of adagrasib plus cetuximab showed antitumor activity and was well tolerated in previously treated patients with KRAS G12C-mutated ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

Currently, we have already known some mechanisms of how TAMs can inhibit the antitumor activity of T cells. Nevertheless, how p53 modulates TIME is still elusive. Researchers found that the loss ...

A research team led by Prof. LIU Chenli from the Shenzhen Institutes of Advanced Technology and Prof. XIAO Yichuan from the Shanghai Institute of Nutrition and Health elucidated the mechanism behind ...

Direct antitumor effects of somatostatin analogs (for example, inhibition of the synthesis and production of autocrine and paracrine growth factors, inhibition of mitogenic signals by growth ...

Pyroptosis, a highly inflammatory type of programmed cell death, has garnered attention for its potential in cancer treatment.

RAS G12D is one of the most frequent mutations in RAS, and when it occurs, it leaves RAS in a permanently active state, causing the cell to proliferate uncontrollably. Examples of the so-called ...